scholarly journals ERECTILE DYSFUNCTION AFTER TRANSURETHRAL PROSTATE RESECTION (TURP) IN PATIENTS WITH LOWER URINARY TRACT SYMPTOMS AT KOJA HOSPITAL, JAKARTA

2021 ◽  
Vol 28 (2) ◽  
pp. 142-146
Author(s):  
Maruto Harjanggi Huseini ◽  
Waluyo Eko Sutarto
Keyword(s):  
Diabetes Mellitus ◽  
Erectile Dysfunction ◽  
Cardiovascular Events ◽  
Prostate Volume ◽  
Specific Antigen ◽  
Transabdominal Ultrasonography ◽  
Urinary Tract Symptoms ◽  
History Of ◽  
Severity Of Erectile Dysfunction ◽  
Transurethral Prostate Resection

Objective: Aim of this study is to identify risk factors associated with erectile dysfunction in post-transurethral prostate resection (TURP) patients for the management of benign prostatic hyperplasia (BPH). Material & Methods: During 2019, 22 patients met the TURP indication criteria in the urology polyclinic of Koja Hospital for symptomatic BPH management. All patients underwent transabdominal ultrasonography to confirm prostate volume and underwent laboratory tests to measure serum prostate-specific antigen (PSA). History of comorbidities such as diabetes mellitus, cardiovascular events, and hypertension was recorded. The patient's sexual function was determined using the International Index of Erectile Function questionnaire (IIEF-5) before surgery and six months postoperatively, where erectile dysfunction was established for scores below 21. Mean comparisons were made to see if there was a significant change in IIEF score six months postoperatively. Results: There were 22 subjects as samples with a mean age of 63 ± 3.8 years, prostate volume 47.64 ± 5.5 mL and a median PSA level of 3.3 [1-47] ng/dL. The comorbidities found in the subjects were diabetes mellitus (22.7%), cardiovascular events (36.4%), and hypertension (27.3%). The mean IIEF-5 score before surgery was 14.55 ± 0.78 and was not significantly different (p= 0.225) with a reevaluation six months after surgery of 14.18 ± 0.76. Conclusion: There was no change in the severity of erectile dysfunction in patients undergoing TURP surgery.

scholarly journals Giant prostatic hyperplasia and its causes

2020 ◽  
Vol 26 (4) ◽  
pp. 237-243
Author(s):  
Marius Anglickis ◽  
Gediminas Platkevičius ◽  
Rokas Stulpinas ◽  
Lina Miklyčiūtė ◽  
Giedrė Anglickienė ◽  
...  
Keyword(s):  
Medical Literature ◽  
Prostate Volume ◽  
Specific Antigen ◽  
Prostatic Hyperplasia ◽  
Prostate Hyperplasia ◽  
Urinary Tract Symptoms ◽  
Prostate Size ◽  
History Of ◽  
Additional Procedure ◽  
Lower Urinary

We present a case of a 59-year-old male who was admitted to the emergency department with urinary retention, with a history of lower urinary tract symptoms, with the value of serum prostate specific antigen level of 100 ng/mL and an estimated prostate size of 800 mL, according to magnetic resonance imaging. A prostate biopsy showed benign prostatic hyperplasia. Transvesical prostatectomy was performed, following additional procedure of transurethral resection of the prostate. To the best of our knowledge, this is the fourth highest prostate volume reported in medical literature. In this paper, we examine the factors that may have influenced the development of giant prostate hyperplasia.

The Cardiovascular Events in Metabolic Surgery Compared to the New Classes of Glucose-Lowering Agents in Patients with T2DM

2021 ◽  
Author(s):  
Najla Shamsi
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Metabolic Surgery ◽  
Cardiovascular Events ◽  
Controlled Trials ◽  
Glucose Lowering ◽  
Randomized Controlled ◽  
History Of

Type 2 Diabetes Mellitus is a prevalent chronic disease with several macrovascular and microvascular complications. Cardiovascular diseases including coronary artery disease and stroke are common macrovascular complication that reduces the quality of life and lead to early mortality. Additionally, they pose enormous socioeconomic burden on the societies and the governments. Therefore, any intervention that reduces the cardiovascular events in patients with diabetes will have positive impact of the patients and the society. Thus, this systematic review aimed to evaluate the cardiovascular events after metabolic surgery in comparison with the new classes of glucose lowering agents in patients with type 2 diabetes mellitus. The review included 11 randomized controlled trials to both GLP-1 RA and SGLT-2 i groups. It also included 7 metabolic surgery studies, 2 of these are randomized controlled trials and the other 5 are observational studies. These studies were the most relevant studies to the research question. The results revealed different baseline demographic and clinical characteristics between the medication trials and metabolic surgery studies. Moreover, it revealed significant reduction in cardiovascular events in metabolic surgery studies when compared to medication trials. It also showed significant HbA1c and weight reduction in the metabolic surgery group. The remission of diabetes was very high in the metabolic surgery group while none of medication trials accomplished diabetes recovery. However, both medication and surgery groups had adverse events. In conclusion, the review is consistent with previous literature. It suggests that metabolic surgery is more effective than medical therapy in reducing cardiovascular events. Although this conclusion should be interpreted with caution due to the differences in baseline characteristics between studies. In general, the review recommends younger adult diabetic patients with obesity and history of established cardiovascular diseases to undergo metabolic surgery. Whereas, older patients with history of cardiovascular disease should be advised to take one of the medications that has been proved to reduce cardiovascular events. Future studies that compare metabolic surgery and the new classes of the glucose lowering agents is recommended to confirm the findings in this review.

scholarly journals New clusters of type 2 diabetes mellitus and their outcomes: relation between pharmacological treatment and previous cardiovascular events

2021 ◽  
Vol 31 (Supplement_2) ◽  
Author(s):  
Claudio Santos ◽  
Sonia Brito-Costa ◽  
Luis Margalho ◽  
Pedro Monteiro
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Pharmacological Treatment ◽  
Cardiovascular Events ◽  
Glycated Haemoglobin ◽  
Research Unit ◽  
Clinical Research Unit ◽  
History Of

Abstract Background Type 2 Diabetes Mellitus (T2DM) is the most common form of diabetes in adults, with 90% to 95% of cases. This study aims to establish clusters and have knowledge about the relationship between previous cardiovascular events and pharmacological treatment for T2DM. Methods 191 participants (EG) with T2DM with the average of 70.3 years (SD = 8.3) and 36 with pre-diabetes (CG) with an average of 62 years (SD = 10.3) who participated in clinical trials at Clinical Research Unit in Cardiology of Coimbra Hospital and Universitary Centre without cognitive difficulties, were divided in 5 different clusters. These were established based on six different variables: body mass index (BMI), age of each individual, age at diagnosis of DMT2, glycated haemoglobin value (HbA1c), homeostatic model that estimates the function of β cells (HOMA2-B) and insulin resistance (HOMA2-IR). Results Cluster 1 presented pre-diabetic individuals (15.9%), while diabetic individuals were divided into clusters 2 (1.8%), 3 (17.6%), 4 (21.1%) and 5 (43.6%). Regarding the study of the prevalence of previous cardiovascular events, the majority of individuals present in the different clusters had history of acute myocardial infarction (AMI). As for the prevalence of pharmacological treatment for DMT2, it was found that metformin was the most used drug. It was observed a relationship between previous AMI and metformin administration in clusters 3 (P = 0.0027; P < 0.05) and 5 (P = 0.0059; P < 0.05). Conclusions It was possible to create different clusters in a sample of the Portuguese population and to observe the existence of dependency relationships between different previous cardiovascular events and pharmacological treatment.

Impact of prostate needle biopsy on erectile function: A prospective study

2019 ◽  
Vol 86 (3) ◽  
pp. 145-147
Author(s):  
Koosha Kamali ◽  
Mostafa Nabizadeh ◽  
Mojtaba Ameli ◽  
Maryam Emami ◽  
Mohadese Mahvari-Habibabadi ◽  
...  
Keyword(s):  
Erectile Dysfunction ◽  
Prostate Specific Antigen ◽  
Prostate Biopsy ◽  
Needle Biopsy ◽  
Prostate Volume ◽  
Specific Antigen ◽  
Prostate Specific Antigen Level ◽  
Antigen Level ◽  
Ultrasound Guided ◽  
The Mean

Background: Needle biopsy of the prostate is a diagnostic method for prostate cancer which is a relatively safe method with low risk of serious complications. The evidences regarding the occurrence of erectile dysfunction following prostate biopsy are controversial. Herein, we aimed at determining the rate of erectile dysfunction in those undergoing transrectal ultrasound-guided prostate biopsy. Method: All candidates for prostate biopsy were enrolled. The International Index of Erectile Function-5 was completed 1 m before and 1, 3, and 6 months after ultrasound-guided prostate biopsy by each patient for erectile dysfunction. Patients with a previous history of erectile dysfunction which due to a positive pathology had received any type of treatment were excluded from the study. Results: Eighty patients with the mean age of 64.8 years, the mean prostate-specific antigen level of 11.64 ng/dL, and the mean prostate volume of 62.43 cc were included. The prostate biopsy result was positive in 38.8% of the cases. No significant relationship was found between erectile dysfunction and prostate-specific antigen level, prostate volume, and the pathology result (P = 0.320, 0.509, and 0.131). The mean questionnaire score 1 month before and after the biopsy was 23 and 18, respectively; it demonstrated a significant difference (P < 0.001). The same score was 17 and 14.5 three and six months after biopsy. The mean score 1 m before and 3 m after biopsy also revealed a significant difference (P < 0.001). Conclusion: Transrectal ultrasound-guided needle biopsy of the prostate causes progressive erectile dysfunction in these patients. This relationship is not affected by the biopsy result, prostate volume, or the prostate-specific antigen level.

scholarly journals Erectile dysfunction in patients of diabetes mellitus: a cross sectional study

2019 ◽  
Vol 6 (8) ◽  
pp. 2941
Author(s):  
Anilkumar Bellad ◽  
Kartik Sahu
Keyword(s):  
Diabetes Mellitus ◽  
Erectile Dysfunction ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Duration Of Diabetes ◽  
Mild Degree ◽  
Patients With Diabetes ◽  
History Of ◽  
One Year

Background: One of the independent risk factor for erectile dysfunction is diabetes mellitus. The present study planned to determine the prevalence and factors associated with ED in DM.Methods: A one year cross-sectional study on a total of 208 patients with type 1 or 2 diabetes. National Institutes of Health (NIH) approved questionnaire for International Index of Erectile Function (IIEF) was used to interview each patient to assess for ED.Results: In this study 12.98% of patients had ED score between 13 to 18 suggestive of mild to moderate ED and 9.62% with 19 to 24 scores suggestive of mild degree. The prevalence of erectile dysfunction was 32.21%. The mean age in patients with erectile dysfunction was significantly high (58.40±10.96 years) compared to those without erectile dysfunction (51.00±11.16 years) (p<0.001) Of the 119 patients with duration of diabetes between one to five years 42.02% had ED and of the 3 patients with duration of more than five years 66.67% had ED (p<0.001). Prevalence of ED was higher in patients with HbA1c levels between 7.0 to 8.5 (32.76%) and >8.5 (37.07%). Prevalence of erectile dysfunction was higher in patients with history of smoking (63.64%) (p<0.001) and alcohol intake (51.85%) (p<0.001). The prevalence of erectile dysfunction was also significantly high in patients with history of hypertension (59.7%) (p<0.001).Conclusions: The ED in patients with diabetes mellitus was significantly prevalent with age, duration of diabetes, history of hypertension, cardiovascular disease, glycemic control and hypertriglyceridemia.

Sign in / Sign up

Export Citation Format

Share Document